Company: EUDAW
Filing Date: 2025-06-24
Form Type: 424B5
Source: 0001641172-25-016185
Chunk: 18

Company: EUDA Health Holdings Ltd
Filing Date: 2025-06-24
Form: 424B5
Chunk 18
---
</div>

The amount of proceeds from this offering will depend upon the number of our ordinary shares sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under this prospectus supplement or fully utilize the Sales Agreement with Chardan, our Agent, as a source of financing.

We intend to use the net proceeds, if any, from the sale of ordinary shares offered hereby for general corporate purposes, including possible acquisitions or the expansion of our business and working capital. From time to time, we engage in preliminary discussions and negotiations with various businesses in order to explore the possibility of an acquisition or investment. However, as of the date of this prospectus supplement, we have not entered into any agreements or arrangements which would make any acquisition or investment probable.

We have not determined the amounts we plan to spend on the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds of this offering. Pending the application of the net proceeds for these purposes, we intend to invest the net proceeds in short-term, investment-grade securities.

| S-11 |

<div align='center'>DILUTION</div>

The net tangible book value of our ordinary shares as of December 31, 2024,was approximately $(2.91) million, or approximately $(0.08) per share. Net tangible book value per share is equal to the amount of our total tangible assets, less total liabilities, divided by the number of ordinary shares outstanding. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of ordinary shares in this offering and the net tangible book value per share of our ordinary shares immediately afterwards.

After giving effect to the sale by us of shares of our ordinary shares in the total aggregate amount of $10.0 million at an assumed offering price of $3.72 per share, the last reported sale price of our ordinary shares on June 20, 2025, on Nasdaq, and after deducting underwriting commissions and estimated offering expenses, our net tangible book value as of December 31 , 2024,would have been approximately $6.3 million, or $0.16 per share. This represents an immediate increase in net tangible book value of $0.24 per share to existing stockholders and an immediate dilution of $3.56 per share to new investors purchasing ordinary shares in this offering.

The following table illustrates this calculation on a per